Audrey la Noce
Psychiatry · Fort Lauderdale, FLNPI 1346676004
Payments from drug & device makers
Across 713 payments — averaging $761.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$526K
- Vanda Pharmaceuticals Inc.$7K
- Otsuka America Pharmaceutical, Inc.$6K
- Johnson & Johnson$1K
- Sunovion Pharmaceuticals Inc.$957
- Teva Pharmaceuticals USA, Inc.$652
- plus $1K from 13 others
What the payments were for
- Consulting fees$5500%
- Speaking & faculty fees$441,26481%
- Travel & lodging$84,83016%
- Food & beverage$15,8853%
- Education$1430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 561 | $526,370 |
| Vanda Pharmaceuticals Inc. | 6 | $6,690 |
| Otsuka America Pharmaceutical, Inc. | 31 | $5,509 |
| Johnson & Johnson | 20 | $1,079 |
| Sunovion Pharmaceuticals Inc. | 30 | $957 |
| Teva Pharmaceuticals USA, Inc. | 14 | $652 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $295 |
| Alkermes, Inc. | 6 | $227 |
| Neurocrine Biosciences, Inc. | 5 | $196 |
| Bausch Health US, LLC | 9 | $170 |
| Axsome Therapeutics, Inc. | 5 | $167 |
| Lundbeck LLC | 10 | $150 |
| Corium, LLC | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Neuronetics, Inc. | 1 | $36 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Brainsway USA Inc | 1 | $26 |
| Sage Therapeutics, LLC | 1 | $19 |
| Indivior Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$519,682
- Fanapt$6,637
- REXULTI$4,786
- SPRAVATO$609
- LATUDA$578
- AUSTEDO$363
- INVEGA SUSTENNA$147
- INVEGA TRINZA$147
- VIVITROL$123
- CAPLYTA$121
- ABILIFY MAINTENA$118
How this compares
$542,672 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $20,116 |
| Clozapine | 19 | $477 |
| Lamotrigine | 17 | $293 |
| Trazodone Hcl | 20 | $102 |
| Sertraline Hcl | 11 | $62 |
| Alprazolam | 32 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $526,370 | $20,11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Fort Lauderdale
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.